Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis

Naval Military Medical University

Status and phase: Enrolling; Phase 3; Phase 2

Conditions: IBD (Inflammatory Bowel Disease); Colitis; Probiotic Intervention

Treatments: Drug: Probiotics 6600; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT07047339

6600

Details and patient eligibility

About

This study was conducted in two phases. In Phase I, 40 UC participants, 40 CD participants, and 40 colitis participants were randomly assigned in a 1:1 ratio to the experimental group and the control group, respectively. The study included a screening period (1 week), a double-blind treatment period (24 weeks), an exit examination (1 day), and a safety follow-up period (4 weeks). After providing informed consent, participants who met the inclusion criteria and those who did not meet the exclusion criteria were randomly assigned, in a 1:1 ratio, to receive either the trial (probiotic 6600 capsules) or the control group (placebo). The clinical remission rate (SCCAI score ≤2 and no single subscore >1) after 24 weeks of treatment was calculated. Mayo score ≤2 and no single subscore >1; CDAI score ≤2 and no single subscore >1) were used as the primary efficacy index.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ulcerative colitis (UC) : met the clinical diagnostic criteria of UC "Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023, Xi 'an)", and modified Mayo score ≥4 points;
2. Crohn's disease (CD) : met the clinical diagnostic criteria of CD "Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (2023, Guangzhou)", and CDAI score ≥220;
3. Colitis: clinical diagnosis of colitis and modified SCCAI score ≥3; 3.
4. The age of signing the informed consent form was from 18 to 75 years old (including the cut-off value, male and female were not limited);
5. Complete medical history;
6. From the time of informed consent until 3 months after the last dose of dose, the participant committed to not having any plans to have children or to have any plans to donate sperm or eggs, and to voluntarily use non-pharmacologic contraception;
7. Fully understand the content, process and possible adverse reactions of the trial, voluntarily participate in the trial, and sign the informed consent.

Exclusion criteria

1. Taking prebiotics or probiotics in the past 2 weeks or allergic to intervention preparations;
2. Short bowel syndrome, abdominal abscess, toxic megacolon, intestinal perforation, active fistula of digestive tract, severe intestinal stenosis with obstructive symptoms, suspected intestinal obstruction, total colectomy;
3. Other autoimmune diseases, hematological diseases, tumors, acute infections, severe hepatic and renal insufficiency (ALT>2 times the upper limit of normal), severe diseases such as neutropenia, heart failure, organic heart disease, viral hepatitis B, liver cirrhosis, renal impairment (serum creatinine > 2mg/dL or 177mmol/L), AIDS And mental disorders;
4. History of psychoactive substance abuse;
5. A history of drug or other dependent substance abuse, or heavy alcohol consumption in the last 2 weeks (i.e. 28 standard units per week for men and 21 standard units per week for women (1 standard unit contains 14g of alcohol, such as 360mL of beer or 25mL of 40% spirits or 150mL of wine); Heavy drinkers during the trial;
6. Pregnant or breastfeeding women, or planning to become pregnant in the next 6 months;
7. Nervous system diseases such as Alzheimer's disease, stroke, Parkinson's disease;
8. Participated in other clinical trials within the past 6 months;
9. Incomplete medical record information (including gender, age, diagnostic information, colonoscopy results, pathological diagnosis results and other demographic data, etc.);
10. Other investigators deemed ineligible for enrollment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 6 patient groups, including a placebo group

UC control group

Placebo Comparator group

Description:

Patients diagnosed with ulcerative colitis (UC) were given one tablet of placebo twice daily (morning and evening after meals) with warm water.

Treatment:

Drug: Placebo

UC experimental group

Experimental group

Description:

Patients diagnosed with ulcerative colitis (UC) were given probiotics 6600 orally twice daily (morning and evening after meals), one tablet each time, with warm water.

Treatment:

Drug: Probiotics 6600

CD control group

Placebo Comparator group

Description:

Patients diagnosed with Crohn's disease (CD) were given one tablet of placebo twice daily (morning and evening after meals) with warm water.

Treatment:

Drug: Placebo

CD experimental group

Experimental group

Description:

Patients diagnosed with Crohn's disease (CD) were given probiotics 6600 orally twice a day (morning and evening after meals), one tablet each time, with warm water.

Treatment:

Drug: Probiotics 6600

Colitis control group

Placebo Comparator group

Description:

Patients diagnosed with colitis (non-ulcerative colitis or Crohn's disease) were given one tablet of placebo twice daily (morning and evening after meals) with warm water.

Treatment:

Drug: Placebo

Colitis experimental group

Experimental group

Description:

For patients diagnosed with colitis (non-ulcerative colitis or Crohn's disease), take probiotic 6600 orally twice daily (morning and evening after meals), one tablet each time, with warm water.

Treatment:

Drug: Probiotics 6600